PhRMA Wary of FDA’s Call for Antibacterial Superiority Trials

Washington Drug Letter
A A
PhRMA is pushing back against the centerpiece of the FDA’s draft guidance on antibacterial drug development, saying superiority trials for antibacterials that treat drug-resistant infections are “neither routinely possible nor consistently ethical.”

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00